158 related articles for article (PubMed ID: 26010599)
1. Median-based incremental cost-effectiveness ratios with censored data.
Bang H; Zhao H
J Biopharm Stat; 2016; 26(3):552-64. PubMed ID: 26010599
[TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery.
McCarthy I; O'Brien M; Ames C; Robinson C; Errico T; Polly DW; Hostin R;
Neurosurg Focus; 2014 May; 36(5):E3. PubMed ID: 24785485
[TBL] [Abstract][Full Text] [Related]
3. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
Wang H; Zhao H
Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
[TBL] [Abstract][Full Text] [Related]
4. Using inverse-weighting in cost-effectiveness analysis with censored data.
Willan AR; Lin DY; Cook RJ; Chen EB
Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
[TBL] [Abstract][Full Text] [Related]
5. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
6. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Sorensen SV; Peng S; Monz BU; Bradley-Kennedy C; Kansal AR
Pharmacoeconomics; 2013 Jul; 31(7):589-604. PubMed ID: 23615895
[TBL] [Abstract][Full Text] [Related]
8. Average cost-effectiveness ratio with censored data.
Bang H; Zhao H
J Biopharm Stat; 2012; 22(2):401-15. PubMed ID: 22251182
[TBL] [Abstract][Full Text] [Related]
9. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
[TBL] [Abstract][Full Text] [Related]
10. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
[No Abstract] [Full Text] [Related]
11. Nonparametric inference for median costs with censored data.
Zhao H; Zuo C; Chen S; Bang H
Biometrics; 2012 Sep; 68(3):717-25. PubMed ID: 22364557
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
13. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.
Laxy M; Wilson ECF; Boothby CE; Griffin SJ
Value Health; 2017 Dec; 20(10):1288-1298. PubMed ID: 29241888
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
15. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial).
Michaels JA; Campbell WB; Brazier JE; Macintyre JB; Palfreyman SJ; Ratcliffe J; Rigby K
Health Technol Assess; 2006 Apr; 10(13):1-196, iii-iv. PubMed ID: 16707070
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
Gafni A; Birch S
Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
[TBL] [Abstract][Full Text] [Related]
19. Bias and precision of measures of survival gain from right-censored data.
Lamb KE; Williamson EJ; Coory M; Carlin JB
Pharm Stat; 2015; 14(5):409-17. PubMed ID: 26218830
[TBL] [Abstract][Full Text] [Related]
20. On estimating medical cost and incremental cost-effectiveness ratios with censored data.
Zhao H; Tian L
Biometrics; 2001 Dec; 57(4):1002-8. PubMed ID: 11764238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
